
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Individuals with high cholesterol who stay on their statin medications over a two-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study.





